Acute myeloid leukemia (AML) pathogenesis
and treatment are currently being better understood at
an accelerated rate. Determining genetic and epigenetic
changes that can identify patients who are at risk of poor
outcomes is therefore desired to optimize treatment options.
Many solid tumors have been reported to overexpress
Inhibitors of DNA binding proteins (ID1), but few research
has looked at the clinical significance of ID1 expression
in AML. Additionally, little research has been focused on
the direct role of ID4 in myeloid malignancies, as well as
its expression and methylation patterns. The aim of the
current study was to assess ID1 and ID4 gene expression
in bone marrow (BM) aspiration specimens of 91 AML
patients, compared with 14 control donors of bone marrow
transplantation (BMT), using real-time polymerase chain
reaction (RT-PCR). Data were correlated with patients’
clinicopathological features, response to treatment, diseasefree survival (DFS), and overall survival (OS) rates.
Results ID1 transcript level was significantly increased
in AML bone marrow samples compared with normal
controls (P = 0.002), while ID4 gene expression showed a
nonsignificant difference (P = 0.717). In addition, there was
a significant increase in ID1 gene expression in fms-like
tyrosine kinase 3 (FLT3) mutant group than fms-like tyrosine
kinase 3 wild group (P = 0.010). The total leukocytic count
(TLC) was significantly higher in patients with high ID1
expression (P = 0.038) and patients with undetected ID4
expression (P = 0.025). No significant associations were
detected between ID1 and ID4 expression levels and
patients’ clinicopathological characteristics and OS rates.
Conclusion In contrast to ID4, overexpressed ID1 can be
adopted as a genetic biomarker for diagnosing AML. ID1
and ID4 expressions did not affect the patients’ OS or DFS. |
